CL2018000317A1 - Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica - Google Patents

Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica

Info

Publication number
CL2018000317A1
CL2018000317A1 CL2018000317A CL2018000317A CL2018000317A1 CL 2018000317 A1 CL2018000317 A1 CL 2018000317A1 CL 2018000317 A CL2018000317 A CL 2018000317A CL 2018000317 A CL2018000317 A CL 2018000317A CL 2018000317 A1 CL2018000317 A1 CL 2018000317A1
Authority
CL
Chile
Prior art keywords
treatment
antibodies
lupus nephritis
nefritis
novedous
Prior art date
Application number
CL2018000317A
Other languages
English (en)
Spanish (es)
Inventor
Scott Ronald Brodeur
Thomas B Freeman
Gerald Henry Nabozny
Meera RAMANUJAM
Paul Scholl
Juergen STEFFGEN
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2018000317A1 publication Critical patent/CL2018000317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2018000317A 2015-09-01 2018-02-05 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica CL2018000317A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27

Publications (1)

Publication Number Publication Date
CL2018000317A1 true CL2018000317A1 (es) 2018-07-20

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000317A CL2018000317A1 (es) 2015-09-01 2018-02-05 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica

Country Status (16)

Country Link
US (3) US20170058038A1 (OSRAM)
EP (1) EP3344655B1 (OSRAM)
JP (2) JP2018529661A (OSRAM)
KR (1) KR20180039172A (OSRAM)
CN (1) CN107922501A (OSRAM)
AU (1) AU2016317028B2 (OSRAM)
BR (1) BR112018001907A2 (OSRAM)
CA (1) CA2993996A1 (OSRAM)
CL (1) CL2018000317A1 (OSRAM)
DK (1) DK3344655T5 (OSRAM)
ES (1) ES2969968T3 (OSRAM)
HU (1) HUE063528T2 (OSRAM)
MX (1) MX390653B (OSRAM)
PH (1) PH12018500445B1 (OSRAM)
PL (1) PL3344655T3 (OSRAM)
WO (1) WO2017040566A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20240149979A (ko) * 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
EA202190094A1 (ru) * 2018-06-29 2021-04-21 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против cd40 для применения в лечении аутоиммунного заболевания
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
ZA936128B (en) 1992-08-21 1995-02-20 Genentech Inc Method for treating a LFA-1 mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
AU2005323515A1 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
ES2354865T3 (es) * 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
RS57114B1 (sr) * 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
AU2012249454B2 (en) * 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
EP3344655B1 (en) 2023-07-26
CA2993996A1 (en) 2017-03-09
ES2969968T3 (es) 2024-05-23
MX2018002447A (es) 2018-06-15
JP2021185169A (ja) 2021-12-09
PH12018500445A1 (en) 2018-09-10
DK3344655T5 (da) 2024-10-07
WO2017040566A1 (en) 2017-03-09
BR112018001907A2 (pt) 2018-09-25
DK3344655T3 (da) 2023-10-09
JP2018529661A (ja) 2018-10-11
PH12018500445B1 (en) 2022-08-10
AU2016317028B2 (en) 2021-09-09
US20170058038A1 (en) 2017-03-02
HUE063528T2 (hu) 2024-01-28
KR20180039172A (ko) 2018-04-17
AU2016317028A1 (en) 2018-02-22
MX390653B (es) 2025-03-21
US20190177420A1 (en) 2019-06-13
EP3344655A1 (en) 2018-07-11
US20230265203A1 (en) 2023-08-24
CN107922501A (zh) 2018-04-17
PL3344655T3 (pl) 2024-02-19

Similar Documents

Publication Publication Date Title
CL2018000317A1 (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica
CL2018000128A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
IL265755A (en) A chimeric antibody receptor for cancer therapy
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CO2017012286A2 (es) Anticuerpos anti-cd40
EA201691541A1 (ru) Новые анти-baff антитела
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CL2017002150A1 (es) Receptores de antígeno quiméricos anti-dll3 y métodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MX2017010864A (es) Anticuerpos contra tau y sus usos.
IL254701A0 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
IL280033A (en) Uses of anti-bcma chimeric antigen receptors
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
MX377052B (es) Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
EA201891299A1 (ru) Терапевтические антитела к cd9
PH12019502694A1 (en) Anti-trkb antibodies
SI3573620T1 (sl) Sestavki za zdravljenje hipertenzije
ZA201907096B (en) Methods of using drift reduction adjuvant compositions
BR112018000513A2 (pt) antagonistas de receptor de cgrp
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201890629A1 (ru) Применение антител к cd40 для лечения волчаночного нефрита